Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2023

28-09-2023 | Antibiotic | REVIEW

The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions

Authors: Rebecca R. Saff, Jamie L. Waldron

Published in: Current Dermatology Reports | Issue 4/2023

Login to get access

Abstract

Purpose of Review

Adverse drug reactions are common in both the inpatient and outpatient settings and lead to limitations in future treatment options. Patch testing, used in conjunction with clinical history and the reaction phenotype, can help to improve identification of the culprit medication and evidence for its use is growing. Here we discuss a standardized approach to patch testing which can lead to accurate and reproducible results.

Recent Findings

Although patch testing may have low sensitivity, specificity is generally high with good utility depending on reaction phenotype and implicated medication. Patch testing has the highest sensitivity for acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms and at the site of fixed drug eruptions. It has the lowest sensitivity in Stevens-Johnson/toxic epidermal necrolysis.

Summary

Patch testing, used in conjunction with clinical history, can help to improve identification of the culprit medication depending on reaction phenotype. Overall, it is safe to perform patch testing with rare risk of reactivation of primary reaction.
Literature
1.
Staicu ML, Vyles D, Shenoy ES, Stone CA, Banks T, Alvarez KS, et al. Penicillin allergy delabeling: a multidisciplinary opportunity. J Allergy Clin Immunol Pract. 2020;8(9):2858-68.e16.PubMedPubMedCentralCrossRef
2.
Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358–63.
3.
Peter JG, Lehloenya R, Dlamini S, Risma K, White KD, Konvinse KC, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract. 2017;5(3):547–63.PubMedPubMedCentralCrossRef
4.
•• Copaescu A, Gibson A, Li Y, Trubiano JA, Phillips EJ. An updated review of the diagnostic methods in delayed drug hypersensitivity. Front Pharmacol. 2020;11:573573. Comprehensive recent review of in vivo and in vitro testing methods for delayed drug reactions.
5.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–80.
6.
Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–96.PubMedCrossRef
7.
•• de Groot AC. Patch testing in drug eruptions: practical aspects and literature review of eruptions and culprit drugs. Dermatitis. 2022;33(1):16–30. Review of patch testing in drug allergy with table of drug concentrations used in patch testing and tables of drugs known to have caused specific types of reactions that have shown positive patch testing results.
8.
Barbaud A, Castagna J, Soria A. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update. Contact Dermat. 2022;86(5):344–56.CrossRef
9.
Barbaud A, Gonçalo M, Bruynzeel D, Bircher A, Dermatitis ESoC. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermat. 2001;45(6):321–8.
10.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.PubMedCrossRef
11.
•• Woodruff CM, Botto N. The role of patch testing in evaluating delayed hypersensitivity reactions to medications. Clin Rev Allergy Immunol. 2022;62(3):548–61. Review providing guidance on patch testing technique.
12.
Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermat. 1996;35(4):234–6.CrossRef
13.
Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62.PubMedCrossRef
14.
Barbaud A. The use of skin testing in the investigation of toxidermia: from pathophysiology to the results of skin testing. Therapie. 2002;57(3):258–62.PubMed
15.
Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152(5):968–74.PubMedCrossRef
16.
Pinho A, Santiago L, Gonçalo M. Patch testing in the investigation of non-immediate cutaneous adverse drug reactions to metamizole. Contact Dermat. 2017;76(4):238–9.CrossRef
17.
Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20(4):461–4.PubMedCrossRef
18.
Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions–a 20-year review. Contact Dermat. 2011;65(4):195–201.CrossRef
19.
Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat. 2010;62(1):47–53.CrossRef
20.
• de Groot AC. Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): A literature review. Contact Dermat. 2022;86(6):443–79. Review on the literature of systemic contact dermatitis including most common culprits, symptoms, and evaluation.
21.
Pinho A, Coutinho I, Gameiro A, Gouveia M, Gonçalo M. Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. J Eur Acad Dermatol Venereol. 2017;31(2):280–7.PubMedCrossRef
22.
Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002;16(16):2223–5.PubMedCrossRef
23.
24.
Novack DE, Braskett M, Worswick SD, Adler BL. Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review. Ann Allergy Asthma Immunol. 2023;130(5):628–36.PubMedCrossRef
25.
Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, et al. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol. 2013;27(3):356–64.PubMedCrossRef
26.
Hamanaka H, Mizutani H, Nouchi N, Shimizu Y, Shimizu M. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol. 1998;23(1):32–4.PubMedCrossRef
27.
Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31(3):436–40.PubMedCrossRef
28.
Schnyder B, Pichler WJ. Allergy to sulfonamides. J Allergy Clin Immunol. 2013;131(1):256–7.e1–5.
29.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843–8.PubMedCrossRef
30.
Assier H, Valeyrie-Allanore L, Gener G, Verlinde Carvalh M, Chosidow O, Wolkenstein P. Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermat. 2017;77(5):297–302.CrossRef
31.
Katayama S, Ota M. Acute generalized exanthematous pustulosis due to a transdermal ketoprofen patch. Contact Dermat. 2022;86(5):425–7.CrossRef
32.
Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JCL. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2022;87(3):632–9.PubMedCrossRef
33.
Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol. 2003;139(9):1181–3.PubMedCrossRef
34.
Sekhon S, Nedorost ST. Patch testing for adverse drug reactions. Cutis. 2017;99(1):49–54.PubMed
35.
• Barbaud A, Romano A. Skin testing approaches for immediate and delayed hypersensitivity reactions. Immunol Allergy Clin North Am. 2022;42(2):307–22. Review of testing in delayed drug reactions including skin prick, intradermal and patch testing.
36.
Caballero ML, Quirce S. Delayed hypersensitivity reactions caused by drug excipients: a literature review. J Investig Allergol Clin Immunol. 2020;30(6):400–8.PubMedCrossRef
37.
Cham PM, Warshaw EM. Patch testing for evaluating drug reactions due to systemic antibiotics. Dermatitis. 2007;18(2):63–77.PubMedCrossRef
38.
Dilley M, Geng B. Immediate and delayed hypersensitivity reactions to antibiotics: aminoglycosides, clindamycin, linezolid, and metronidazole. Clin Rev Allergy Immunol. 2022;62(3):463–75.PubMedCrossRef
39.
Konvinse KC, Phillips EJ, White KD, Trubiano JA. Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. Curr Opin Infect Dis. 2016;29(6):561–76.PubMedPubMedCentralCrossRef
40.
Doña I, Pérez-Sánchez N, Salas M, Barrionuevo E, Ruiz-San Francisco A, Hernández Fernández de Rojas D, et al. Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones. J Allergy Clin Immunol Pract. 2020;8(8):2707–14.e2.
41.
Seitz CS, Bröcker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allergy. 2009;39(11):1738–45.PubMedCrossRef
42.
Hausermann P, Scherer K, Weber M, Bircher AJ. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. Dermatology. 2005;211(3):277–80.PubMedCrossRef
43.
Hoosen K, Mosam A, Dlova NC, Grayson W. An update on adverse cutaneous drug reactions in HIV/AIDS. Dermatopathology (Basel). 2019;6(2):111–25.PubMedCrossRef
44.
De Raeve L, Song M, Van Maldergem L. Adverse cutaneous drug reactions in AIDS. Br J Dermatol. 1988;119(4):521–3.PubMedCrossRef
45.
Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4(2):426–8.PubMedCrossRef
46.
van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection. Lancet. 1991;338(8764):431–3.PubMedCrossRef
47.
Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Biomed Pharmacother. 2000;54(1):45–9.
48.
Krantz MS, Stone CA, Abreo A, Phillips EJ. Oral challenge with trimethoprim-sulfamethoxazole in patients with “sulfa” antibiotic allergy. J Allergy Clin Immunol Pract. 2020;8(2):757-60.e4.PubMedCrossRef
49.
Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139(1):49–58.PubMedCrossRef
50.
Lehloenya RJ, Todd G, Wallace J, Ngwanya MR, Muloiwa R, Dheda K. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol. 2016;175(1):150–6.PubMedCrossRef
51.
Dickel H, Geier J, Kreft B, Pfützner W, Kuss O. Comparing reliabilities of strip and conventional patch testing. Contact Dermat. 2017;76(6):342–9.CrossRef
52.
Dickel H, Bruckner TM, Erdmann SM, Fluhr JW, Frosch PJ, Grabbe J, et al. The “strip” patch test: results of a multicentre study towards a standardization. Arch Dermatol Res. 2004;296(5):212–9.PubMedCrossRef
53.
Kim BE, Goleva E, Kim PS, Norquest K, Bronchick C, Taylor P, et al. Side-by-side comparison of skin biopsies and skin tape stripping highlights abnormal stratum corneum in atopic dermatitis. J Invest Dermatol. 2019;139(11):2387-9.e1.PubMedPubMedCentralCrossRef
54.
Corazza M, Toni G, Musmeci D, Scuderi V, Amendolagine G, Borghi A. Dermoscopy of patch test reactions: study of applicability in differential diagnosis between allergic and irritant reactions. Br J Dermatol. 2019;180(2):429–30.PubMedCrossRef
55.
56.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32.PubMedCrossRef
57.
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2.PubMedCrossRef
58.
Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183–92.PubMedPubMedCentralCrossRef
59.
Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997;27(2):175–81.PubMedCrossRef
60.
Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027–37.PubMedCrossRef
61.
Copaescu A, Mouhtouris E, Vogrin S, James F, Chua KYL, Holmes NE, et al. The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions. J Allergy Clin Immunol Pract. 2021;9(5):2010-5.e4.PubMedCrossRef
Metadata
Title
The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions
Authors
Rebecca R. Saff
Jamie L. Waldron
Publication date
28-09-2023
Publisher
Springer US
Keyword
Antibiotic
Published in
Current Dermatology Reports / Issue 4/2023
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-023-00405-9

Other articles of this Issue 4/2023

Current Dermatology Reports 4/2023 Go to the issue

REVIEW

Artificial Intelligence Bringing Newer Paradigms in the Diagnosis, Treatment, and Management of Psoriasis

REVIEW

JAK Inhibitor Use for the Inpatient Dermatologist

HOT TOPIC

Oral Minoxidil Therapy in Hair Loss: Where Do We Stand?

REVIEW

Update on Cutaneous Small Vessel Vasculitis: Terminology, Morphology, Diagnostic Evaluation, and Management

REVIEW

Incontinence-Associated Dermatitis: a Practical Guide for the Consulting Dermatologist

REVIEW

The Future of Patch Testing: Reimbursement Models, Workforce Shortages, and Negotiating in the House of Medicine